INS and diabetic cardiomyopathy: As a crucial step during the development of diabetic cardiomyopathy, CD36, the major cardiac LCFA transporter, permanently relocates to the sarcolemma, which increases LCFA uptake and subsequently myocellular lipid deposition, ultimately leading to inhibition of insulin signaling, as exemplified by decreased insulin-stimulated Akt-Ser473 phosphorylation [5].